Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-06
2008-05-06
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266310, C544S284000, C544S286000, C544S287000
Reexamination Certificate
active
10993147
ABSTRACT:
A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB. IA and IB have the following structures where Z has the formula shown below and the rest of the variables are defined herein
REFERENCES:
patent: 3177218 (1965-04-01), Brown
patent: 4128643 (1978-12-01), Merkel et al.
patent: 4211867 (1980-07-01), Rasmussen
patent: 4287341 (1981-09-01), Hess et al.
patent: 4496571 (1985-01-01), Yellin et al.
patent: 4732916 (1988-03-01), Satoh et al.
patent: 4748165 (1988-05-01), Jones et al.
patent: 4874864 (1989-10-01), Schnur et al.
patent: 4948891 (1990-08-01), Schnur et al.
patent: 4948901 (1990-08-01), Schnur et al.
patent: 5086057 (1992-02-01), Sasagawa
patent: 5124328 (1992-06-01), Fisher et al.
patent: 5352704 (1994-10-01), Okuyama et al.
patent: 5362902 (1994-11-01), Barnish et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5637439 (1997-06-01), Kaneko et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5885985 (1999-03-01), Macdonald et al.
patent: 5889025 (1999-03-01), Lohray et al.
patent: 5952381 (1999-09-01), Chen et al.
patent: 5962530 (1999-10-01), Engel et al.
patent: 6020349 (2000-02-01), Ankerson et al.
patent: 6030985 (2000-02-01), Gentile et al.
patent: 6054556 (2000-04-01), Huby et al.
patent: 6060589 (2000-05-01), Stark et al.
patent: 6127343 (2000-10-01), Ankersen et al.
patent: 6180603 (2001-01-01), Frey, II
patent: 6225331 (2001-05-01), Cupps et al.
patent: 6297233 (2001-10-01), Stein et al.
patent: 6313093 (2001-11-01), Frey, II
patent: 6391878 (2002-05-01), Cupps et al.
patent: 6638927 (2003-10-01), Renhowe et al.
patent: 6716840 (2004-04-01), Chu et al.
patent: 2003/0195187 (2003-10-01), Boyce et al.
patent: 2003/0207814 (2003-11-01), Boyce et al.
patent: 2003/0229025 (2003-12-01), Xiao et al.
patent: 2004/0019049 (2004-01-01), Boyce et al.
patent: 2005/0059662 (2005-03-01), Boyce et al.
patent: 31 08 322 (1981-12-01), None
patent: 0343894 (1989-11-01), None
patent: WO 96/24580 (1996-08-01), None
patent: WO 97/19911 (1997-06-01), None
patent: WO 97/41119 (1997-11-01), None
patent: WO 98/07420 (1998-02-01), None
patent: WO 99/64002 (1999-12-01), None
patent: WO 00/03973 (2000-01-01), None
patent: WO 00/17191 (2000-03-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/10842 (2001-02-01), None
patent: WO 01/55106 (2001-08-01), None
patent: WO 01/55107 (2001-08-01), None
patent: WO 01/55109 (2001-08-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 02/18327 (2002-03-01), None
patent: WO 02/062776 (2002-08-01), None
patent: WO 02/081443 (2002-10-01), None
patent: WO 03/099818 (2003-12-01), None
Runti, C.; DeNardo, M.; Ulian F., “Fusaric Acid Derivatives and Analogues as Possible Antihypertensive Drugs,” II Farmaco Edizione Scientifica, vol. 36(4), pp. 260-268 (1981), published in Italy by the Society of Italian Pharmaceutical Science. This is an English-language document.
Asagarasu, A. et al., “Synthesis of Dipeptide-Type Human Immunodeficiency Virus (HIV) Protease Inhibitors with a Binding Unit to GP120,”Chem. Pham. Bull., vol. 46, No. 5, pp. 867-870, 1998, published by Pharmaceutical Society of Japan.
Rossi, M. et al., “A C-terminal fragment of Agouti-related protein increases feeding and antagonizes the effect of alpha-melanocyte stimulating hormone in vivo,”Endocrinology, vol. 139, No. 10, pp. 4428-4431, 1998, published by The Endocrine Society.
Cupps et al. (1998): STN International, CAPLUS database, Columbus (Ohio), Accession No. 1998: 388504.
Hadley, M. E. et al., “The Proopiomelanocortin System,”Ann. N. Y. Acad. Sci., 885:1, pp. 1-21, 1999.
Smolnik, R. et al., “Brain Potentials and Attention after Acute and Subchronic Intranasal Administration of ACTH 4-10 and Desacetyl-α-MSH in Humans,”Neuroendocrinology, vol. 70, pp. 63-72, 1999, published by S. Karger AG, Basel.
Fehm, H. L. et al., “The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4-10Decreases Body Fat in Humans,”J. Clin. Endocrinology&Metabolism, vol. 86, No. 3, pp. 1144-1148, 2001, published by the Endocrine Society.
Smith, R. A. et al., “Discovery and Parallel Synthesis of a New Class of Cathepsin K Inhibitors,”Bioorganic&Medicinal Chemistry Letters, vol. 11, pp. 2951-2954, 2001, published by Elsevier Science Ltd.
Shadiak, A. M. et al. “Intranasal Delivery of a Melanocortin for the Treatment of Sexual Dysfunction,” Presentation at Fifth International Conference Exploring the Rapidy Developing Area of Nasal Drug Delivery, Mar. 21 and 22, Le Meridien Hotel, Piccadilly, London, United Kingdom.
U.S. Appl. No. 10/850,967, filed May 21, 2004, Boyce et al.
Julia, M. et al., “Amidines and guanidines related to congocidine. III. Urea and trazene diamidines,”Bull. Soc. Chim. Fr., No. 1, pp. 376-382, 1968, published by Masson Editeur, Paris, France.
Mountjoy, K. G. et al., “The Cloning of a Family of Genes That Encode the Melanocortin Receptors,”Science, vol. 257, pp. 1248-1251, Aug. 28, 1992.
Lu, D. et al., “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,”Nature, vol. 371, pp. 799-802, Oct. 27, 1994.
Huszar, D. et al., “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice,”Cell, vol. 88, pp. 131-141, Jan. 10, 1997, published by Cell Press.
Ollmann, M. M. et al., “Antagonism of Central melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,”Science, vol. 278, pp. 135-138, Oct. 3, 1997.
Kiefer, L.L. et al., “Mutations in the Carboxyl Terminus of the Agouti Protein Decrease Agouti Inhibition of Ligand Binding to the Melanocortin Receptors,”Biochemistry, vol. 36, pp. 2084-2090, 1997, published by American Chemical Society.
Fong, T. M. et al., “ART (Protein Product of Agouti-Related Transcript) as an Antagonist of MC-3 and MC-4 Receptors,”Biochemical and Biophysical Res. Comm., vol. 237, pp. 629-631, 1997, published by Academic Press.
Wolff, M. E., “Burger's Medicinal Chemistry and Drug Discovery 5thEdition,” pp. 975-977 (1995), M. E. Wolff (ed.); published by John Wiley & Sons (New York, NY).
Banker, G. S. et al., “Modern Pharmaceutics, 3rdEdition,” 596 and 451 (1996), G. S. Banker and C. T. Rhodes (eds.); published by Marcel Dekker, Inc. (New York, NY).
West, A. R., “Solid State Chemistry and Its Applications,” pp. 358 and 365 (1988), A. R. West (ed.); published by John Wiley & Sons (New York, NY).
Goodfellow, V. S. et al., “The Melanocortin System and its Role in Obesity and Cachexia,”Current Top. Med. Chem., vol. 3, No. 8, pp. 855-883 (2003); published by Bentham Science Publishers Ltd. (San Francisco, CA).
Fisher, S. L. et al., Int. J. Obes. Relat. Metab. Disord. Suppl. 1, pp. 54-48 (Feb. 1999); published by the American Dietetic Association (Chicago, IL).
Boyce Rustum S.
Phillips James
Speake Jason D.
Chiron Corporation
Glaxo SmithKline
Kathardekar Vinit
Meara Joseph P.
Truong Tamthom N
LandOfFree
Quinazolinone compounds with reduced bioaccumulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolinone compounds with reduced bioaccumulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolinone compounds with reduced bioaccumulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3931864